Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study to Evaluate Escitalopram in Obsessive-compulsive Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of OCD~* A minimum score of 16 on the Yale Brown Obsessive-Compulsive Scale (YBOCS) at both the screening and baseline visits~Exclusion Criteria:~* Lifetime history of psychosis or cognitive dysfunction due to a general medical condition or substance use~* A primary diagnosis of another Axis I psychiatric disorder~* Alcohol or other substance abuse or dependence within the last 6 months~* Unstable medical condition~* Clinically significant laboratory abnormality~* Failure of a previous 10-week trial of citalopram of at least 40 mg/day or escitalopram 20 mg/day~* Active suicidality~* History of violent behavior in the past year or current risk of serious violence~* A history of sensitivity to citalopram or escitalopram~* Use of other investigational drugs within 30 days of baseline or other psychotropic drugs or herbs within 14 days of baseline (28 days for fluoxetine)~* Need for concurrent psychotherapeutic intervention~* Pregnant or lactating females.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Open Label Escitalopram 10-20 mg/daily (Type: EXPERIMENTAL): Fourteen patients who met criteria for the study were enrolled in the open-label phase. Thirteen of these patients completed the open-label phase, while one patient was terminated early due to side effects.
- Randomizationn Placebo 10-20 mg daily (Type: PLACEBO_COMPARATOR): Of the thirteen patients who completed the open label part of the trial, twelve demonstrated at least minimal improvement (CGI-I \< 3) and agreed to continue with the randomized, double-blind phase. These patients were randomized to escitalopram (n=5) or placebo (n=7).
- Randomization Escitalopram 10-20 mg/daily (Type: ACTIVE_COMPARATOR): Of the thirteen patients who completed the open label part of the trial, twelve demonstrated at least minimal improvement (CGI-I \< 3) and agreed to continue with the randomized, double-blind phase. These patients were randomized to escitalopram (n=5) or placebo (n=7).

Based on this trial design, predict the completion outcome and termination type (if applicable).